EP Patent

EP3246017A1 — Stable liquid formulation of amg 416 hcl (etelcalcetide)

Assigned to Amgen Inc · Expires 2017-11-22 · 8y expired

What this patent protects

A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.

USPTO Abstract

A liquid formulation comprising a peptide agonist of the calcium sensing receptor and method of preparing and using the formulation are provided.

Drugs covered by this patent

Patent Metadata

Patent number
EP3246017A1
Jurisdiction
EP
Classification
—
Expires
2017-11-22
Drug substance claim
No
Drug product claim
No
Assignee
Amgen Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.